Rekah Pharmaceutical Industry Stock Retained Earnings
| REKA Stock | ILA 1,279 46.00 3.47% |
Rekah Pharmaceutical Industry fundamentals help investors to digest information that contributes to Rekah Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Rekah Stock. The fundamental analysis module provides a way to measure Rekah Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rekah Pharmaceutical stock.
Rekah |
Rekah Pharmaceutical Industry Company Retained Earnings Analysis
Rekah Pharmaceutical's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Rekah Pharmaceutical Retained Earnings | 49 M |
Most of Rekah Pharmaceutical's fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rekah Pharmaceutical Industry is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
| Competition |
Based on the latest financial disclosure, Rekah Pharmaceutical Industry has a Retained Earnings of 49 M. This is 94.74% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The retained earnings for all Israel stocks is 99.47% higher than that of the company.
Did you try this?
Run Fundamental Analysis Now
Fundamental AnalysisView fundamental data based on most recent published financial statements |
| All Next | Launch Module |
Rekah Fundamentals
| Return On Equity | 0.0222 | |||
| Return On Asset | 0.0208 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.05 % | |||
| Current Valuation | 316.92 M | |||
| Shares Outstanding | 11.41 M | |||
| Shares Owned By Insiders | 37.27 % | |||
| Shares Owned By Institutions | 42.66 % | |||
| Price To Book | 1.11 X | |||
| Price To Sales | 0.63 X | |||
| Revenue | 263.95 M | |||
| Gross Profit | 65.16 M | |||
| EBITDA | 36.2 M | |||
| Net Income | 6.62 M | |||
| Cash And Equivalents | 31.61 M | |||
| Cash Per Share | 2.77 X | |||
| Total Debt | 101.23 M | |||
| Debt To Equity | 1.01 % | |||
| Current Ratio | 1.99 X | |||
| Book Value Per Share | 14.39 X | |||
| Cash Flow From Operations | 21.17 M | |||
| Earnings Per Share | 0.32 X | |||
| Number Of Employees | 399 | |||
| Beta | 0.0605 | |||
| Market Capitalization | 193.93 M | |||
| Total Asset | 437.09 M | |||
| Retained Earnings | 49 M | |||
| Working Capital | 156 M | |||
| Current Asset | 246 M | |||
| Current Liabilities | 90 M | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.05 % | |||
| Net Asset | 437.09 M | |||
| Last Dividend Paid | 0.87 |
About Rekah Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rekah Pharmaceutical Industry's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rekah Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rekah Pharmaceutical Industry based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Rekah Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Rekah Pharmaceutical's short interest history, or implied volatility extrapolated from Rekah Pharmaceutical options trading.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rekah Pharmaceutical Industry. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Rekah Stock analysis
When running Rekah Pharmaceutical's price analysis, check to measure Rekah Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rekah Pharmaceutical is operating at the current time. Most of Rekah Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Rekah Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rekah Pharmaceutical's price. Additionally, you may evaluate how the addition of Rekah Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |